Dr. Kudo on Cost-Effectiveness Analysis of Lenvatinib Versus Sorafenib
September 16th 2018
Masatoshi Kudo, MD, PhD, professor and chairman, Department of Gastroenterology and Hepatology, Kindai University, Osaka, Japan, discusses the results of a cost-effectiveness analysis of lenvatinib versus sorafenib in unresectable hepatocellular carcinoma in Japan.